Moderna won a significant patent battle in the UK Appeals Court, confirming the validity of its patent on a modified mRNA technology used in COVID-19 vaccines. The ruling upholds a previous decision that Pfizer and BioNTech's Comirnaty vaccine infringes on Moderna’s EP’949 patent, which covers the replacement of uracil bases with N1-methyl-pseudouridine to enhance mRNA stability and immune response. This decision bolsters Moderna’s intellectual property position globally in the competitive mRNA vaccine market, following parallel legal actions in the US and Europe. CEO Stéphane Bancel emphasized ongoing enforcement efforts to protect Moderna’s technology amidst intense global competition.